Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rumors here of a major silver find. It's all speculation until the NI 43-101 but still, look at the playa's here.
I am in, got the dip I was looking for so now my question is: What is my investment going to be worth in 2 years.
COVID 19 cure/ float 10 million/ market cap 4 million.
What more do you want???????????????????? QNTA .096
The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"),
NEWS COVID 19 cure 4 million market cap = https://www.accesswire.com/626095/Medolifes-Therapeutic-Scorpion-Peptide-Proves-Successful-in-Treating-COVID-19-Patients-in-Dominican-Republic-Study
KATIE::: BAR THE DOOR!!
Float 10,190,900
What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Wed, January 27, 2021, 5:57 AM
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
Medolife's Therapeutic Scorpion Peptide Proves Successful in Treating COVID-19 Patients in Dominican Republic Study
Wed, January 27, 2021, 5:57 AM
BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
"The data proving the efficacy that Escozine has on a multitude of improved patient parameters is consistent with the rapid symptom relief I experienced while on site," said Dr. Annabelle Morgan, Cell and Developmental Biologist and one of Medolife's leading scientists. She noted, "What is even more astonishing is that 100% of patients tested negative for COVID-19 within 5-10 days of treatment."
Could be that is what they want to do...keep the noise level to an absolute minimum. "old" retail shareholders are not on their priority list, they could just get rid of old shareholders with a reverse split, or bring them along..providing they don't make too much noise, during final number crunching to go public.
Been there, done that.
Time is the enemy of many penny players, if you outlast them then you get to cherry pick. I grabbed some more under .01 today as well, the story has not changed, just perceptions.
yea, but still a good day and a very promising future here.
Outstanding Shares 42,513,415
Surprise!!, or a data fluke?
Details
Details TableToday's Open $0.178
Previous Close $0.072
Day's Range $0.178 - $0.178
52 Week Range $0.0013 - $0.178
Beta (5 Year) -9.13
Average Volume (10 Day) 377,870
Put/Call Ratio (1 Day) --
Put/Call Ratio (30 Day) --
Earnings TTM (GAAP)
Details
Earnings TableEarnings Per Share (09/30/2008) --
Price/Earnings --
Forward P/E --
Price to Earnings / Growth (PEG)
--
Not much of a Canadian following yet either, I think the timing is about perfect for a two year hold. The NI 43-101 is the key to either .50 to $30.00 a share, pick one I guess.
here is a press release from last Oct. that I find interesting
Silver Dollar hires Tetra Tech as technical adviser
2020-10-21 10:06 ET - News Release
Mr. Michael Romanik reports
SILVER DOLLAR RETAINS TETRA TECH AS TECHNICAL ADVISORS FOR THE LA JOYA SILVER PROJECT IN DURANGO, MEXICO
Silver Dollar Resources Inc. has hired Tetra Tech Inc. as a technical adviser to work alongside the company in guiding future exploration efforts on the La Joya silver project in Durango, Mexico.
Tetra Tech was previously involved with the project, providing technical support services between 2010 and 2015, when SilverCrest Mines Inc. owned and operated the project. The Tetra Tech team consists of independent qualified persons, as defined by National Instrument 43-101, who have visited the project on several occasions, completed two inferred mineral resource estimates and developed a preliminary economic assessment study on behalf of SilverCrest.
"We are thrilled to be working with the Tetra Tech team, whose previous experience and knowledge of the La Joya project is already paying dividends," said Michael Romanik, president of Silver Dollar. "This enables us to hit the ground running as we prepare for our initial drilling program. A formal historical data compilation is in progress and will be used for the development of an updated geological model to aid in identifying regional hot spots for follow-up exploration."
About the La Joya project
Under the terms of the definitive agreement between Silver Dollar and First Majestic (see news release dated Aug. 10, 2020), Silver Dollar has been granted an exclusive option to acquire an initial 80-per-cent interest and, if exercised, a second option to acquire an additional 20-per-cent interest for an aggregate 100-per-cent interest in First Majestic's La Joya silver-copper-gold property. The property, located in the southeastern portion of the state of Durango in the Mexican silver belt, consists of 15 mineral concessions, totalling 4,646 hectares, and hosts the main mineralized trend, the Santo Nino deposit and the Coloradito deposit.
The property is situated approximately 75 kilometres directly southeast of the state capital city of Durango in a prolific mineralized region with past-producing and operating mines, including: Grupo Mexico's San Martin mine; Industrias Penoles's Sabinas mine; Pan American Silver's La Colorada mine; and First Majestic's La Parrilla and Del Toro silver mines. Access and infrastructure near the property are considered excellent, with highway, rail and power lines nearby.
P. James F. Barr, PGeo, of Tetra Tech, a qualified person as defined in NI 43-101, has reviewed and approved the technical content in this press release.
About Silver Dollar Resources Inc.
Silver Dollar Resources is a mineral exploration company focused on creating shareholder value by finding and developing economic precious metal and base metal deposits. Silver Dollar's projects are located in two of the prolific mining jurisdictions in the world and include the advanced-exploration-stage/development-stage La Joya silver project in Durango, Mexico, and the discovery-stage Pakwash Lake and Longlegged Lake properties in the Red Lake mining district of Ontario, Canada. The company has an aggressive growth strategy and is actively reviewing projects in mining-friendly jurisdictions internationally for potential acquisition.
We seek Safe Harbor.
That is just fine, market cap under 1 million and on it's way to being reborn. Synergy and Lazier plays are way over-followed now so this one should be::: winna winna chicken dinna at some point in the future
Buying here for a 1 year hold is my personal plan with all R/M plays.. it works..
Thanks for that, it should be obvious. This is not the type of stock to jump in and out of, there will come a future day with just one press release and all the professional money that follows mining plays will be on this like a dog pile on a rabbit.
Grow a pair, and make some money...
So who throws $6.5 milly into one company? Eric Sprott does I guess, you think he knows something?
Was waiting for this day. Now to wait for the NI43-101.
There is a rumble in the jungle over this one, some very heavy hitters are jumping on board, including Billionaire Eric Sproutt is throwing his own money into this one.
That geologist is no slouch either, this one should be a ride,(personal WAG $15.00 in two years)
what we don't have is a solid value, it's all guess and hope, expect the share price to flop like a fish for a while, but the hope is there.
On the legal side of every stock the filings must become up to date before a reverse merger can happen.
I'm done here, argue all you want, I make far too much money to be tied up with differences of opinion.. have a good life.
Great, any CEO that lets the cat out of the bag to retail investors is headed for trouble.
I see more positives with this holding than negatives, this is a reverse merger play of sorts so I want to see what the non-disclosure results are.
Then and only then can you define a value
This is all I needed for a currently 4 million market cap company:
Cliff Emmons
CEO at IIoT-Oxys
Greater Boston Area500+ connections
About
I am a passionate visionary executive leader with extensive experience in creating, building, and transforming businesses in the USA, India, and China, some at Fortune 500 companies, as well as startups. I’ve led organizations with over 200 employees and multi-million USD budgets.
I'm highly skilled and recognized in leveraging innovative technologies to build businesses that generate significant & sustained revenue growth. My expertise includes:
- Technology-driven business strategy development & execution
- Innovative Business Models utilizing IIoT, Edge Computing, and AI/ ML technologies
- Organic product & service portfolio creation and delivery
- Global organization design, scaling & optimization
Sorry, that is not the way it works. All filings must be brought up to date first.
Know what you own.
oh ouch, I am well versed in custodian plays and have been for a while.
My opinion is this market cap is too high for where it is, not it's potential. who's the buyer? where's the filings?
And as you well know it's a long way from FINRA accepting the share structure to completed reverse merger .. but you know that
Patented Polarization Technology Brings Increased Effectiveness in Venom-To-Drug Development
BURBANK, Calif., Jan. 21, 2021 /PRNewswire/ -- Medolife Rx, Inc., ("Medolife") the majority owner of Quanta, Inc. (OTCPK: QNTA) today announced that Medolife and The Ministry of Environment of The Dominican Republic signed an exclusive 10-year agreement with automatic renewal. This groundbreaking partnership encompasses exclusive rights for investigations, production, and distribution world-wide for the venom of a unique species of scorpions indigenous to the Dominican Republic. Medolife will focus on the R&D of pharmaceutical-grade products, as well as clinical evidence-based nutraceuticals, using its proprietary process of its polarization technology, developed by CEO, Dr. Arthur Mikaelian.
A recent Business Insider article estimated scorpion venom to be the most expensive liquid in the world, valued at $39 million dollars-per-gallon. Scorpion venom is currently in active research by large pharmaceutical companies for its therapeutic use in treating cancer, COVID-19, viral diseases, inflammation, and pain, all of which are independently multi-billion-dollar industries. Medolife is a pioneer in venom-to-drug development. With Medolife's Dominican Republic Scorpion Reservation being one of the largest natural breeding grounds for scorpions on earth. Medolife will bring its 30+ years of research and expertise to help locate, study and develop groundbreaking formulas and pharmaceutical-grade medications for consumer use. This agreement also allows for Medolife to expand its existing infrastructure, facilities, and certified pharmaceutical lab.
Medolife's close relationship with the Dominican Republic government dates back to 2007, which significantly contributed to research and FDA trials of a new generation of natural pharmaceutical-grade and evidence-based nutraceutical products. Medolife CEO, Dr. Arthur Mikaelian said "We could not feel more humbled by the trust the Dominican Republic Government has shown to us. We have worked closely with them for the past 14 years and are incredibly excited to continue our research and trials with them as a partner for the next 10-years and beyond." He continued by saying "This partnership has the possibilities to bring so many new life-changing formulas to the world. From cancer medications to viral and immune system therapies, we are truly just scratching the surface of what this incredible peptide can do for mankind."
Over the years, The Government of The Dominican Republic and Medolife have undertaken extensive research and expeditions to locate and identify specific scorpion species that have therapeutic and medical values. Marina Hernandez, Head of the Genetic Resources Department of the Biodiversity Directorate with the Dominican Republic Ministry of Environment said "A long term partnership between our Government and Medolife gives us much hope. We have experienced first-hand the marvelous results Dr. Mikaelian has discovered through his research. With our ongoing support of Medolife's research, we wish to contribute to the significant improvement of the lives of people in the Dominican Republic, and the world at large."
About Medolife:
Medolife Rx, Inc. is a Wyoming corporation, founded by Dr. Arthur Mikaelian, a pioneer of polarization technology, which has been awarded U.S. Patent 8,097,284 B2 as it pertains to Polarized Scorpion Venom solution and the method for making it. Dr. Mikaelian's technical education began at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological Psychology; he then went on to complete his post-doctorate work at Vernadsky. He also earned an MBA from the University of Bologna in Italy. You can find more about Medolife at: http://medolife.com/
About Quanta:
Quanta, Inc. ("Quanta") utilizes a cutting-edge technology platform that applies advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind polarization process used by Quanta has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Quanta has the opportunity to upend how commercial products are made and the benefits from them. Already, we see multitrillion dollar global industries benefiting from the technology used by Quanta. You can find more about Quanta at: https://buyquanta.com/.
More Foundation building:
And this company has only a 4 million market cap...
Visionary CEO Cliff Emmons
I am a passionate visionary executive leader with extensive experience in creating, building, and transforming businesses in the USA, India, and China, some at Fortune 500 companies, as well as startups. I’ve led organizations with over 200 employees and multi-million USD budgets.
I'm highly skilled and recognized in leveraging innovative technologies to build businesses that generate significant & sustained revenue growth. My expertise includes:
- Technology-driven business strategy development & execution
- Innovative Business Models utilizing IIoT, Edge Computing, and AI/ ML technologies
- Organic product & service portfolio creation and delivery
- Global organization design, scaling & optimization
Foundation building time:
Shore up the authorized to be used for purchases.
NDA signed.
now it is waiting game.
Market cap and share structure are in line with a long term hold
new position, one year hold
Reason 1
As previously disclosed, in Q1 of 2020 we successfully completed a pilot program with a Fortune 500 Pharma company, and signed a collaboration agreement with Aingura IIoT, S.L.. These two accomplishments have allowed the Company and its partner to prepare use cases to renew engagements with all of the Company’s earlier prospects and reach out to new ones. Our sales and marketing efforts continue to result in expanding our key targeted markets and serving a diverse group of clients,” continued Mr. Emmons.
Reason 2
IIOT-OXYS, Inc. Enters into NDA with New England-Based Biotech Start-Up
CAMBRIDGE, MA / ACCESSWIRE / January 20, 2021 / IIOT-OXYS, Inc. (OTC PINK:ITOX) announced the execution of a Non-Disclosure Agreement (NDA) with a New England based biotechnology start-up.
Cliff Emmons, CEO of IIOT-OXYS, Inc., stated, “This customer provides products and services to the biomanufacturing industry that ensures high quality and efficacious products. It’s provided those products and services for over a decade and has received substantial private investment as recently as last year. Our customer engagement process consists of several steps, the first being the execution of an NDA, which then allows us to quickly define a problem statement of interest to the client, which then leads to a definition of scope of work for the first contract. We are very pleased to be working with this forward-looking company that’s commercialized several innovations to ensure productivity, quality, and data-integrity for their customers. We look forward to working with their domain experts to see where our edge computing and machine learning algorithms will add the most value to their biomanufacturing products and services.”
“This represents an expansion to our current pharmaceutical intelligent manufacturing segments. As previously disclosed, in Q1 of 2020 we successfully completed a pilot program with a Fortune 500 Pharma company, and signed a collaboration agreement with Aingura IIoT, S.L.. These two accomplishments have allowed the Company and its partner to prepare use cases to renew engagements with all of the Company’s earlier prospects and reach out to new ones. Our sales and marketing efforts continue to result in expanding our key targeted markets and serving a diverse group of clients,” continued Mr. Emmons.
Transfer Agent has verified the share structure as of 1/19/2021
Held at DTC is the important number
Outstanding Shares
37,869,999
01/19/2021
Restricted
33,339,498
01/19/2021
Unrestricted
4,530,501
01/19/2021
Held at DTC
2,061,161
01/19/2021
That was my second buying opportunity since I took my first position here, and the gods were with me on that last stink bid.
Waiting for the first anniversary, watching for the NI 43-101, that is the focus for my research..
I am not going anywhere on this holding..I think I know the potential here. It just needs a little more of the proof...
Who's talking float, that has never been verified, the outstanding is also unknown
yea that is what I said..
with billions in the float
you found it!, share structure through the roof with billions in the float if you know how to read filings... that is why unverified shell pinkies need to have a whole new level of research before you buy in.
I am going to wait on this one, fish always smell from the head first.
Anyone verify that bogus message from the outgoing whoever?
You sure your not getting played?
EMDF XL Rent / E Med Future, Inc. Synergy Management was appointed custodian by the Nevada courts. Synergy will be reinstating the corporation, settling with the transfer agent and finding a viable candidate to take control over the coming weeks. There are several parties we are in talks with that are interested.
SBOX is part of the reverse merger market and has changed over the past year since the toe-rag investors have found this sector of the market so emotions run high with unprofessional traders. That being said this company needs to lower it's market cap. The share structure is ideal but a little tight, it will be exciting once this shell is verified and Lazer finds a buyer. Then all the ingredients are there for an outstanding double digit run. A dark pinky still unverified right now it is an overpriced crap shoot.
Took my first position to put it on my list, if you have level two you can see my bids from .05 through .10, they are all GTC's so they will remain in effect during my two month sailing venture away from whiners
Market Cap 9,467,500
Pink No Information
Dark or Defunct
Not gonna fly until the market cap is back under 3,000,000. Even that is way too high for what it is.
On March 12, 2020, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.
David Lazar, 29, has been CEO and Chairman of the Company since May 16, 2018.
-----------------------
Taking way too long, something not right, this one may have been hijacked like so many others.
That's close but the mining industry works by:
1. Total Mine life (in years)
2. Total time to payoff of mine startup expenses and property
3. Cost to extract.
The in-situ (in the ground) deposit divided by the production rate of mining equals mine life
So just for giggles (as an example) a project with a 20 year mine life and a 4 year payback period means 16 years of unburdened profit minus the cost to exploit.
Or just pick a number and throw it at the wall and see if it sticks.